Topics

Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

17:25 EDT 15 Aug 2019 | SCRIP

Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it...

      

Related Stories

 

Original Article: Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi

NEXT ARTICLE

More From BioPortfolio on "Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi"

Quick Search

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...